Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer

E. N. Knyazev; K. A. Fomicheva; D. S. Mikhailenko; K. M. Nyushko; T. R. Samatov; B. Ya. Alekseev; M. Yu. Shkurnikov

doi:10.1007/s10517-016-3357-7

Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer

作者: Knyazev E.¹, Fomicheva K.², Mikhailenko D.², Nyushko K.², Samatov T.¹, Alekseev B.², Shkurnikov M.¹^,2
隶属关系:
1. BioClinicum Center Research and Development Company
2. Medical Radiology Center
期: 卷 161, 编号 1 (2016)
页面: 108-111
栏目: Article
URL: https://journals.rcsi.science/0007-4888/article/view/237158
DOI: https://doi.org/10.1007/s10517-016-3357-7
ID: 237158

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅存取

详细
作者简介
参考
统计

详细

Peripheral blood plasma profiles of circulating microRNA expression were analyzed in patients with prostatic cancer and benign hyperplasia. In prostatic cancer, significant increase in hsa-miR-619-5p and hsa-miR-1184 microRNA expression and significant decrease in hsalet-7b-5p and hsa-let-7c-5p microRNA expression were observed. The role of the relationship between the microRNA expression and the activities and functions of host genes with introns encoding these microRNA is discussed.